Patents by Inventor Christophe Combadiere
Christophe Combadiere has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10253087Abstract: The invention relates to a peptide useful as a CCR2 non-competitive antagonist peptide.Type: GrantFiled: May 1, 2018Date of Patent: April 9, 2019Assignee: Sorbonne UniversityInventors: Christophe Combadiere, Florian Sennlaub, Constance Auvynet, Sylvian Chemtob, Christiane Quiniou
-
Publication number: 20180251523Abstract: The invention relates to a peptide comprising the following amino acid sequence useful as a CCR2 non competitive antagonist peptide.Type: ApplicationFiled: May 1, 2018Publication date: September 6, 2018Applicant: UNIVERSITE PIERRE ET MARIE CURIE (Paris 6)Inventors: Christophe Combadiere, Florian Sennlaub, Constance Auvynet, Sylvian Chemtob, Christiane Quiniou
-
Publication number: 20170051040Abstract: The invention relates to a peptide comprising the following amino acid sequence Thr-Phe-Leu-Lys or Thr-Phe-Leu-Lys-Cys, useful as a CCR2 non competitive antagonist peptide.Type: ApplicationFiled: September 2, 2016Publication date: February 23, 2017Applicant: UNIVERSITE PIERRE ET MARIE CURIE (Paris 6)Inventors: Christophe Combadiere, Florian Sennlaub, Constance Auvynet, Sylvain Chemtob, Christiane Quiniou
-
Patent number: 9434766Abstract: The invention relates to a peptide comprising the following amino acid sequence Thr-Phe-Leu-Lys (SEQ ID NO: 17) or Thr-Phe-Leu-Lys-Cys (SEQ ID NO: 1), useful as a CCR2 non-competitive antagonist peptide.Type: GrantFiled: June 26, 2012Date of Patent: September 6, 2016Assignee: Universite Pierre Et Marie Curie (Paris 6)Inventors: Christophe Combadiere, Florian Sennlaub, Constance Auvynet, Sylvian Chemtob, Christiane Quiniou
-
Publication number: 20150011477Abstract: The invention relates to a peptide comprising the following amino acid sequence Thr-Phe-Leu-Lys or Thr-Phe-Leu-Lys-Cys, useful as a CCR2 non competitive antagonist peptide.Type: ApplicationFiled: June 26, 2012Publication date: January 8, 2015Applicant: UNIVERSITE PIERRE ET MARIE CURIEInventors: Christophe Combadiere, Florian Sennlaub, Constance Auvynet, Sylvain Chemtob, Christiane Quiniou
-
Patent number: 8198042Abstract: The susceptibility of human macrophages to human immunodeficiency virus (HIV) infection depends on cell surface expression of the human CD4 molecule and CC cytokine receptor 5. CCR5 is a member of the 7-transmembrane segment superfamily of G-protein-coupled cell surface molecules. CCR5 plays an essential role in the membrane fusion step of infection by some HIV isolates. The establishment of stable, nonhuman cell lines and transgenic mammals having cells that coexpress human CD4 and CCR5 provides valuable tools for the continuing research of HIV infection. In addition, antibodies which bind to CCR5, CCR5 variants, and CCR5-binding agents, capable of blocking membrane fusion between HIV and target cells represent potential anti-HIV therapeutics for macrophage-tropic strains of HIV.Type: GrantFiled: May 14, 2004Date of Patent: June 12, 2012Assignee: The United States of America, represented by the Secretary, Department of Health and Human ServicesInventors: Christophe Combadiere, Philip M. Murphy
-
Publication number: 20120141538Abstract: The present invention concerns modulators of the CX3CR1 receptor. More specifically, antagonists and agonists of the CX3CR1 receptor have been identified. These antagonists and agonists can be used for treating an inflammatory disorder, an autoimmune disorder, a cardiovascular disease, a neurodegenerative disease, a graft versus host disease, a behavioral disorder, a cicatrisation disorder, a viral infection, cancer or pain. They may also be used as an adjuvant in a vaccine composition.Type: ApplicationFiled: December 16, 2009Publication date: June 7, 2012Applicant: UNIVERSITE PIERRE ET MARIE CURIE -PARIS VIInventors: Guy Gorochov, Karim Dorgham, Christophe Combadiere, Philippe Deterre
-
Publication number: 20110117101Abstract: The susceptibility of human macrophages to human immunodeficiency virus (HIV) infection depends on cell surface expression of the human CD4 molecule and CC cytokine receptor 5. CCR5 is a member of the 7-transmembrane segment superfamily of G-protein-coupled cell surface molecules. CCR5 plays an essential role in the membrane fusion step of infection by some HIV isolates. The establishment of stable, nonhuman cell lines and transgenic mammals having cells that coexpress human CD4 and CCR5 provides valuable tools for the continuing research of HIV infection. In addition, antibodies which bind to CCR5, CCR5 variants, and CCR5-binding agents, capable of blocking membrane fusion between HIV and target cells represent potential anti-HIV therapeutics for macrophage-tropic strains of HIV.Type: ApplicationFiled: January 24, 2011Publication date: May 19, 2011Inventors: Christophe Combadiere, Philip M. Murphy, Edward A. Berger
-
Publication number: 20080241167Abstract: The susceptibility of human macrophages to human immunodeficiency virus (HIV) infection depends on cell surface expression of the human CD4 molecule and CC cytokine receptor 5. CCR5 is a member of the 7-transmembrane segment superfamily of G-protein-coupled cell surface molecules. CCR5 plays an essential role in the membrane fusion step of infection by some HIV isolates. The establishment of stable, nonhuman cell lines and transgenic mammals having cells that coexpress human CD4 and CCR5 provides valuable tools for the continuing research of HIV infection. In addition, antibodies which bind to CCR5, CCR5 variants, and CCR5-binding agents, capable of blocking membrane fusion between HIV and target cells represent potential anti-HIV therapeutics for macrophage-tropic strains of HIV.Type: ApplicationFiled: March 7, 2008Publication date: October 2, 2008Inventors: Christophe Combadiere, Yu Feng, Ghalib Alkhatib, Edward A. Berger, Philip M. Murphy, Christopher C. Broder, Paul E. Kennedy
-
Patent number: 7374872Abstract: The susceptibility of human macrophages to human immunodeficiency virus (HIV) infection depends on cell surface expression of the human CD4 molecule and CC cytokine receptor 5. CCR5 is a member of the 7-transmembrane segment superfamily of G-protein-coupled cell surface molecules. CCR5 plays an essential role in the membrane fusion step of infection by some HIV isolates. The establishment of stable, nonhuman cell lines and transgenic mammals having cells that coexpress human CD4 and CCR5 provides valuable tools for the continuing research of HIV infection. In addition, antibodies which bind to CCR5, CCR5 variants, and CCR5-binding agents, capable of blocking membrane fusion between HIV and target cells represent potential anti-HIV therapeutics for macrophage-tropic strains of HIV.Type: GrantFiled: November 7, 2006Date of Patent: May 20, 2008Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Christophe Combadiere, Philip M. Murphy
-
Publication number: 20070087990Abstract: The susceptibility of human macrophages to human immunodeficiency virus (HIV) infection depends on cell surface expression of the human CD4 molecule and CC cytokine receptor 5. CCR5 is a member of the 7-transmembrane segment superfamily of G-protein-coupled cell surface molecules. CCR5 plays an essential role in the membrane fusion step of infection by some HIV isolates. The establishment of stable, nonhuman cell lines and transgenic mammals having cells that coexpress human CD4 and CCR5 provides valuable tools for the continuing research of HIV infection. In addition, antibodies which bind to CCR5, CCR5 variants, and CCR5-binding agents, capable of blocking membrane fusion between HIV and target cells represent potential anti-HIV therapeutics for macrophage-tropic strains of HIV.Type: ApplicationFiled: November 7, 2006Publication date: April 19, 2007Inventors: Christophe Combadiere, Yu Feng, Ghalib Alkhatib, Edward Berger, Philip Murphy, Christopher Broder, Paul Kennedy
-
Patent number: 7151087Abstract: The susceptibility of human macrophages to human immunodeficiency virus (HIV) infection depends on cell surface expression of the human CD4 molecule and CC cytokine receptor 5. CCR5 is a member of the 7-transmembrane segment superfamily of G-protein-coupled cell surface molecules. CCR5 plays an essential role in the membrane fusion step of infection by some HIV isolates. The establishment of stable, nonhuman cell lines and transgenic mammals having cells that coexpress human CD4 and CCR5 provides valuable tools for the continuing research of HIV infection. In addition, antibodies which bind to CCR5, CCR5 variants, and CCR5-binding agents, capable of blocking membrane fusion between HIV and target cells represent potential anti-HIV therapeutics for macrophage-tropic strains of HIV.Type: GrantFiled: October 31, 2003Date of Patent: December 19, 2006Assignee: The United States of America as represented by the Department of Health and Human ResourcesInventors: Christophe Combadiere, Yu Feng, Ghalib Alkhatib, Edward A. Berger, Philip M. Murphy, Christopher C. Broder, Paul E. Kennedy
-
Publication number: 20050118677Abstract: The susceptibility of human macrophages to human immunodeficiency virus (HIV) infection depends on cell surface expression of the human CD4 molecule and CC cytokine receptor 5. CCR5 is a member of the 7-transmembrane segment superfamily of G-protein-coupled cell surface molecules. CCRS plays an essential role in the membrane fusion step of infection by some HIV isolates. The establishment of stable, nonhuman cell lines and transgenic mammals having cells that coexpress human CD4 and CCR5 provides valuable tools for the continuing research of HIV infection. In addition, antibodies which bind to CCR5, CCR5 variants, and CCR5-binding agents, capable of blocking membrane fusion between HIV and target cells represent potential anti-HIV therapeutics for macrophage-tropic strains of HIV.Type: ApplicationFiled: May 14, 2004Publication date: June 2, 2005Inventors: Christophe Combadiere, Philip Murphy
-
Publication number: 20040259785Abstract: The susceptibility of human macrophages to human immunodeficiency virus (HIV) infection depends on cell surface expression of the human CD4 molecule and CC cytokine receptor 5. CCR5 is a member of the 7-transmembrane segment superfamily of G-protein-coupled cell surface molecules. CCR5 plays an essential role in the membrane fusion step of infection by some HIV isolates. The establishment of stable, nonhuman cell lines and transgenic mammals having cells that coexpress human CD4 and CCR5 provides valuable tools for the continuing research of HIV infection. In addition, antibodies which bind to CCR5, CCR5 variants, and CCR5-binding agents, capable of blocking membrane fusion between HIV and target cells represent potential anti-HIV therapeutics for macrophage-tropic strains of HIV.Type: ApplicationFiled: October 31, 2003Publication date: December 23, 2004Applicant: The Govt. of the USA, as represented by the Secretary of the Dept. of Health & Human ServicesInventors: Christophe Combadiere, Yu Feng, Ghalib Alkhatib, Edward A. Berger, Philip M. Murphy, Christopher C. Broder, Paul E. Kennedy
-
Publication number: 20030195348Abstract: The susceptibility of human macrophages to human immunodeficiency virus (HIV) infection depends on cell surface expression of the human CD4 molecule and CC cytokine receptor 5. CCR5 is a member of the 7-transmembrane segment superfamily of G-protein-coupled cell surface molecules. CCR5 plays an essential role in the membrane fusion step of infection by some HIV isolates. The establishment of stable, nonhuman cell lines and transgenic mammals having cells that coexpress human CD4 and CCR5 provides valuable tools for the continuing research of HIV infection. In addition, antibodies which bind to CCR5, CCR5 variants, and CCR5-binding agents, capable of blocking membrane fusion between HIV and target cells represent potential anti-HIV therapeutics for macrophage-tropic strains of HIV.Type: ApplicationFiled: May 15, 2003Publication date: October 16, 2003Applicants: The United States of America, represented by the Secretary,, Department of Health and Human ServicesInventors: Christophe Combadiere, Yu Feng, Ghalib Alkhatib, Edward A. Berger, Philip M. Murphy, Christopher C. Broder, Paul E. Kennedy
-
Patent number: 6383746Abstract: A functional promoter for the chemokine receptor CCR5 is provided. The invention provides a nucleic acid sequence for the promoter and methods of reducing inflammation and susceptibility to HIV infection by suppressing the activity of the promoter.Type: GrantFiled: October 21, 1998Date of Patent: May 7, 2002Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Florence Guignard, Philip M. Murphy, Christophe Combadiere, H. Lee Tiffany